MET and prostate carcinoma: Rhodocetin-αβ-induced breakdown of the tumor vessel wall barrier may be relevant also for other NRP1- and MET-expressing malignancies in which VM occurs, for example glioma/astrocytoma [10, 43], prostate cancer [20, 44], and gastric cancer [17, 45].